Literature DB >> 19364850

In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.

Anthony M Nicasio1, Jared L Crandon, David P Nicolau.   

Abstract

Tigecycline is a glycylcycline with activity against Enterobacteriaceae, including multidrug-resistant isolates of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamase (ESBL) and carbapenemases. Herein, we used an in vivo murine thigh model to characterize the pharmacodynamic profile of tigecycline against genotypically and phenotypically diverse K. pneumoniae and E. coli isolates. Doses of 3.125 to 300 mg/kg, divided 1 to 6 times daily, were administered subcutaneously against six (two nonresistant, one carbapenemase, and three ESBL producing) K. pneumoniae strains and five (two nonresistant and three ESBL producing) E. coli strains. The phenotypic profile (reported tigecycline MIC) for all isolates ranged from 0.125 to 2 microg/ml. Mean correlation coefficients of free (f) drug exposures (percentage of the dosing interval that free drug concentration remained above the MIC [fT>MIC], the ratio of the free drug area under the concentration-time curve/MIC [fAUC/MIC], and the ratio of maximum concentration of free drug in serum/MIC) for all 11 isolates were 0.595, 0.969, and 0.897, respectively. The fAUC/MIC was the pharmacodynamic parameter that best described the efficacy of tigecycline against both E. coli and K. pneumoniae. Interestingly, reductions in the number of CFU were noted even though doses achieved an fT>MIC of 0%. With respect to fAUC/MIC in the neutropenic model, the cumulative 80% and 50% effective pharmacodynamic indexes (EI(80) and EI(50)) for all 11 isolates were 8.4 and 4.7, respectively. An experiment in nonneutropenic mice infected with an ESBL-producing E. coli and K. pneumoniae isolate resulted in the lowest tigecycline fAUC/MIC EI(80) and EI(50) values at 1.8 and 1.0 for E. coli and 1.7 and 1.6 for K. pneumoniae. While the phenotypic profile of tigecycline appeared to drive efficacy irrespective of ESBL or carbapenemase production, the presence of a competent immune system markedly reduced this required exposure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364850      PMCID: PMC2704680          DOI: 10.1128/AAC.01678-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Authors:  S A Van Wart; J S Owen; E A Ludwig; A K Meagher; J M Korth-Bradley; B B Cirincione
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.

Authors:  R Hope; M Warner; N A C Potz; E J Fagan; D James; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2006-10-11       Impact factor: 5.790

3.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.

Authors:  R Naesens; J P Ursi; J Van Schaeren; A Jeurissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-19       Impact factor: 3.267

Review 5.  The pharmacokinetic and pharmacodynamic profile of tigecycline.

Authors:  Alison K Meagher; Paul G Ambrose; Thaddeus H Grasela; Evelyn J Ellis-Grosse
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

6.  Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.

Authors:  Joseph R DiPersio; Michael J Dowzicky
Journal:  Int J Antimicrob Agents       Date:  2007-03-21       Impact factor: 5.283

7.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.

Authors:  Marc H Scheetz; Chao Qi; John R Warren; Michael J Postelnick; Teresa Zembower; Arlene Obias; Gary A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

9.  Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Authors:  A K Meagher; J A Passarell; B B Cirincione; S A Van Wart; K Liolios; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

10.  Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Authors:  Patricia A Bradford; Peter J Petersen; Mairead Young; C Hal Jones; Mark Tischler; John O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

View more
  14 in total

1.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.

Authors:  Chin-Fang Su; Chien Chuang; Yi-Tsung Lin; Yu-Jiun Chan; Jung-Chung Lin; Po-Liang Lu; Ching-Tai Huang; Jann-Tay Wang; Yin-Ching Chuang; L Kristopher Siu; Chang-Phone Fung
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-14       Impact factor: 3.267

4.  Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model.

Authors:  Fabio Cafini; Jose Yuste; Maria-Jose Giménez; David Sevillano; Lorenzo Aguilar; Luis Alou; Elisa Ramos-Sevillano; Martha Torrico; Natalia González; Ernesto García; Pilar Coronel; Jose Prieto
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

5.  Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.

Authors:  Pornpan Koomanachai; Jared L Crandon; Mary Anne Banevicius; Li Peng; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

6.  Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period.

Authors:  Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

7.  In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae.

Authors:  Jennifer Le; Barbara McKee; Warunee Srisupha-Olarn; David S Burgess
Journal:  J Clin Med Res       Date:  2011-05-19

8.  Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumonia in a systemic Septicaemia infection mouse model.

Authors:  Chieh-Yu Pan; Jian-Chyi Chen; Te-Li Chen; Jen-Leih Wu; Cho-Fat Hui; Jyh-Yih Chen
Journal:  Mar Drugs       Date:  2015-04-14       Impact factor: 5.118

9.  Antibacterial effect evaluation of moxalactam against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae with in vitro pharmacokinetics/pharmacodynamics simulation.

Authors:  Chen Huang; Beiwen Zheng; Wei Yu; Tianshui Niu; Tingting Xiao; Jing Zhang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2018-01-15       Impact factor: 4.003

10.  Efficacy of Appropriate Antimicrobial Therapy on the Survival of Patients With Carbapenem Nonsusceptible Klebsiella Pneumoniae Infection: A Multicenter Study in Taiwan.

Authors:  Yi-Tsung Lin; Chien Chuang; Chin-Fang Su; Yu-Jiun Chan; Lih-Shinn Wang; Ching-Tai Huang; Yin-Ching Chuang; L Kristopher Siu; Chang-Phone Fung
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.